{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T12:01:04Z","timestamp":1784030464053,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Edaravone has been widely used in amyotrophic lateral sclerosis (ALS) treatment, and a sublingual (SL) tablet has been developed to offer a more convenient alternative for injection. We present a cost-utility analysis to comprehensively evaluate the costs and health outcomes of oral and intravenous edaravone for the treatment of ALS in Chinese medical context.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Cost-utility analysis of SL tablets of edaravone versus intravenous edaravone at home was performed by constructing a 20-year Markov model of ALS stage 1\u20134 and death. The data were extracted from the literature with model assumptions. Typical sensitivity analysis and scenario analysis for administering SL tablets at home versus intravenous tablets at the hospital were performed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the base case analysis, with SL tablets and intravenous injections both at home, the model estimated an additional cost of \u00a512,670.04 and an additional 0.034 QALYs over 20\u00a0years (life time) of modeling analysis, and the ICER was \u00a5372,648.24 per QALY. However, in the scenario of intravenous administration at the hospital, SL tablet was demonstrated dominance to intravenous injection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Using 3 times the GDP per capita of China in 2023 as the threshold, the SL tablet edaravone was not cost-effective in the context of home treatment for both formulationst, but was dominance to intravenous injection in hospital treatment. The results highlighted the importance of treatment context for health economic analysis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-024-03381-w","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T10:03:17Z","timestamp":1730109797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis"],"prefix":"10.1186","volume":"19","author":[{"given":"Chang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangxu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libo","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"issue":"3","key":"3381_CR1","doi-asserted-by":"publisher","first-page":"17085","DOI":"10.1038\/nrdp.2017.85","volume":"20","author":"O Hardiman","year":"2017","unstructured":"Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;20(3):17085. https:\/\/doi.org\/10.1038\/nrdp.2017.85.","journal-title":"Nat Rev Dis Primers"},{"issue":"22","key":"3381_CR2","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1056\/NEJM200105313442207","volume":"344","author":"LP Rowland","year":"2001","unstructured":"Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001;344(22):1688\u2013700. https:\/\/doi.org\/10.1056\/NEJM200105313442207.","journal-title":"N Engl J Med"},{"key":"3381_CR3","doi-asserted-by":"publisher","unstructured":"Chi\u00f2 A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler. 2009;10(5\u20136):310\u201323. https:\/\/doi.org\/10.3109\/17482960802566824.","DOI":"10.3109\/17482960802566824"},{"issue":"5","key":"3381_CR4","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1136\/jnnp-2019-322317","volume":"91","author":"L Xu","year":"2020","unstructured":"Xu L, Chen L, Wang S, Feng J, Liu L, Liu G, et al. Incidence and prevalence of amyotrophic lateral sclerosis in urban China: a national population-based study. J Neurol Neurosurg Psychiatry. 2020;91(5):520\u20135. https:\/\/doi.org\/10.1136\/jnnp-2019-322317.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"3381_CR5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1136\/jnnp-2018-318974","volume":"90","author":"KY Jun","year":"2019","unstructured":"Jun KY, Park J, Oh KW, Kim EM, Bae JS, Kim I, et al. Epidemiology of ALS in Korea using nationwide big data. J Neurol Neurosurg Psychiatry. 2019;90(4):395\u2013403. https:\/\/doi.org\/10.1136\/jnnp-2018-318974.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"03","key":"3381_CR6","first-page":"70","volume":"17","author":"Y Luo","year":"2020","unstructured":"Luo Y, Huang R, Luo Y. The economic burden of patients with amyotrophic lateral sclerosis in southwest China and its influencing factors. Pract J Clin Med. 2020;17(03):70\u20134.","journal-title":"Pract J Clin Med"},{"issue":"7","key":"3381_CR7","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jfma.2013.01.008","volume":"114","author":"CP Tsai","year":"2015","unstructured":"Tsai CP, Wang KC, Hwang CS, Lee IT, Lee CT. Incidence, prevalence, and medical expenditures of classical amyotrophic lateral sclerosis in Taiwan, 1999\u20132008. J Formos Med Assoc. 2015;114(7):612\u20139. https:\/\/doi.org\/10.1016\/j.jfma.2013.01.008.","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"3381_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.20344\/amp.6590","volume":"29","author":"AC Pinho","year":"2016","unstructured":"Pinho AC, Gon\u00e7alves E. Are amyotrophic lateral sclerosis caregivers at higher risk for health problems? Acta Med Port. 2016;29(1):56\u201362. https:\/\/doi.org\/10.20344\/amp.6590.","journal-title":"Acta Med Port"},{"issue":"3","key":"3381_CR9","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.clinthera.2020.01.006","volume":"42","author":"X Chen","year":"2020","unstructured":"Chen X, Sun Z, Wang J, Liang W, Zhao X, Wang Y, et al. Predicting the pharmacokinetic characteristics of edaravone intraven ous injection and sublingual tablet through modeling and simulation. Clin Ther. 2020;42(3):428\u201338. https:\/\/doi.org\/10.1016\/j.clinthera.2020.01.006.","journal-title":"Clin Ther"},{"issue":"10","key":"3381_CR10","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/j.clinthera.2018.08.009","volume":"40","author":"J Wang","year":"2018","unstructured":"Wang J, Chen X, Yuan B, Wang W, Xu C, Zhao W, et al. Bioavailability of edaravone sublingual tablet versus intravenous infusion in healthy male volunteers. Clin Ther. 2018;40(10):1683\u201391. https:\/\/doi.org\/10.1016\/j.clinthera.2018.08.009.","journal-title":"Clin Ther"},{"key":"3381_CR11","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2147\/CEOR.S359025","volume":"14","author":"NA Ronquest","year":"2022","unstructured":"Ronquest NA, Paret K, Lucas A, Ciepielewska M, Hagan M. Quantifying the value of introducing an oral drug delivery option for edaravone: a review of analyses evaluating the economic impact of oral versus intravenous formulations. Clinicoecon Outcomes Res. 2022;14:499\u2013511. https:\/\/doi.org\/10.2147\/CEOR.S359025.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"3","key":"3381_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.neurol.2021.06.009","volume":"178","author":"M Michel","year":"2022","unstructured":"Michel M, Le Page E, Laplaud DA, Wardi R, Lebrun C, Zagnoli F, et al. Cost-utility of oral methylprednisolone in the treatment of multiple sclerosis relapses: results from the COPOUSEP trial. Rev Neurol (Paris). 2022;178(3):241\u20138. https:\/\/doi.org\/10.1016\/j.neurol.2021.06.009.","journal-title":"Rev Neurol (Paris)"},{"issue":"20","key":"3381_CR13","doi-asserted-by":"publisher","first-page":"4930","DOI":"10.3390\/cancers15204930","volume":"15","author":"P Phisalprapa","year":"2023","unstructured":"Phisalprapa P, Kositamongkol C, Korphaisarn K, Akewanlop C, Srimuninnimit V, Supakankunti S, et al. Cost-utility and budget impact analyses of oral chemotherapy for stage III colorectal cancer: real-world evidence after policy implementation in Thailand. Cancers (Basel). 2023;15(20):4930. https:\/\/doi.org\/10.3390\/cancers15204930.","journal-title":"Cancers (Basel)"},{"issue":"38","key":"3381_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta23380","volume":"23","author":"M Scarborough","year":"2019","unstructured":"Scarborough M, Li HK, Rombach I, Zambellas R, Walker AS, McNally M, Atkins B, et al. Oral versus intravenous antibiotics for bone and joint infections: the OVIVA noninferiority RCT. Health Technol Assess. 2019;23(38):1\u201392. https:\/\/doi.org\/10.3310\/hta23380.","journal-title":"Health Technol Assess"},{"issue":"5","key":"3381_CR15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1056\/NEJM199707313370525","volume":"337","author":"MH Eckman","year":"1997","unstructured":"Eckman MH, Steere AC, Kalish RA, Pauker SG. Cost effectiveness of oral as compared with intravenous antibiotic therapy for patients with early Lyme disease or Lyme arthritis. N Engl J Med. 1997;337(5):357\u201363. https:\/\/doi.org\/10.1056\/NEJM199707313370525.","journal-title":"N Engl J Med"},{"key":"3381_CR16","unstructured":"Pharmacoeconomic Review Report: Edaravone (Radicava): (Mitsubishi Tanabe Pharma Corporation). Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. 2019. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK542526\/. Accessed Apr 2019."},{"issue":"7\u20138","key":"3381_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/21678421.2018.1484925","volume":"19","author":"NJ Thakore","year":"2018","unstructured":"Thakore NJ, Lapin BR, Kinzy TG, Pioro EP. Deconstructing progression of amyotrophic lateral sclerosis in stages: a Markov modeling approach. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(7\u20138):483\u201394. https:\/\/doi.org\/10.1080\/21678421.2018.1484925.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"3381_CR18","unstructured":"National Bureau of statistics of China: China statistical yearbook. 2023. https:\/\/www.stats.gov.cn\/sj\/ndsj\/2023\/indexch.htm. Accessed 20 Feb 2024."},{"issue":"1\u20132","key":"3381_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/s0022-510x(01)00616-5","volume":"191","author":"GM Kiebert","year":"2001","unstructured":"Kiebert GM, Green C, Murphy C, Mitchell JD, O\u2019Brien M, Burrell A, et al. Patients\u2019 health-related quality of life and utilities associated with different stages of amyotrophic lateral sclerosis. J Neurol Sci. 2001;191(1\u20132):87\u201393. https:\/\/doi.org\/10.1016\/s0022-510x(01)00616-5.","journal-title":"J Neurol Sci"},{"issue":"3\u20134","key":"3381_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3109\/21678421.2013.872149","volume":"15","author":"AR Jones","year":"2014","unstructured":"Jones AR, Jivraj N, Balendra R, Murphy C, Kelly J, Thornhill M, et al. Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(3\u20134):285\u201391. https:\/\/doi.org\/10.3109\/21678421.2013.872149.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"3","key":"3381_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/14660820410021339","volume":"6","author":"K Beusterien","year":"2005","unstructured":"Beusterien K, Leigh N, Jackson C, Miller R, Mayo K, Revicki D. Integrating preferences into health status assessment for amyotrophic lateral sclerosis: the ALS Utility Index. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6(3):169\u201376. https:\/\/doi.org\/10.1080\/14660820410021339.","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"3381_CR22","doi-asserted-by":"publisher","unstructured":"Tavakoli M. Disease progression in amyotrophic lateral sclerosis. Identifying the cost-utility of riluzole by disease stage. Eur J Health Econ. 2002;3(3):156\u201365. https:\/\/doi.org\/10.1007\/s10198-002-0110-0.","DOI":"10.1007\/s10198-002-0110-0"},{"key":"3381_CR23","doi-asserted-by":"publisher","unstructured":"Mosegui GG, Vianna CM, Rodrigues MS, Valle PM, Silva FV. Cost-effectiveness analysis of oral rehydration therapy compared to intravenous rehydration for acute gastroenteritis without severe dehydration treatment. J Infect Public Health. 2019;12(6):816\u201321. https:\/\/doi.org\/10.1016\/j.jiph.2019.05.001.","DOI":"10.1016\/j.jiph.2019.05.001"},{"issue":"10","key":"3381_CR24","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/S1473-3099(19)30288-9","volume":"19","author":"LF Ibrahim","year":"2019","unstructured":"Ibrahim LF, Huang L, Hopper SM, Dalziel K, Babl FE, Bryant PA. Intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis: a cost-effectiveness analysis. Lancet Infect Dis. 2019;19(10):1101\u20138. https:\/\/doi.org\/10.1016\/S1473-3099(19)30288-9.","journal-title":"Lancet Infect Dis"},{"key":"3381_CR25","doi-asserted-by":"publisher","unstructured":"Towne SD Jr, Liu X, Li R, Smith ML, Maddock JE, Tan A, et al. Social and structural determinants of health inequities: socioeconomic, transportation-related, and provincial-level indicators of cost-related forgone hospital care in China. Int J Environ Res Public Health. 2021;18(11):6113. https:\/\/doi.org\/10.3390\/ijerph18116113.","DOI":"10.3390\/ijerph18116113"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03381-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03381-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03381-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T02:05:53Z","timestamp":1730167553000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03381-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3381"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03381-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"assertion":[{"value":"18 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"400"}}